Quick Answer
Avalo Therapeutics, Inc. reported Total Revenue of $59.0 thousand for fiscal year 2025.
Avalo Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $59.0K | -86.6% |
| 2024 | $441.0K | -77.1% |
| 2023 | $1.92M | -89.3% |
| 2022 | $18.05M | +234.4% |
| 2021 | $5.40M | -19.4% |
| 2020 | $6.70M | -0.8% |
| 2019 | $6.75M | -4.0% |
| 2018 | $7.03M | -74.7% |
| 2017 | $27.81M | +2312.3% |
| 2016 | $1.15M | — |
| 2015 | $0.00 | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | -100.0% |
| September 30, 2024 | $249.0K | +5.5% | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | -100.0% | -100.0% |
| September 30, 2023 | $236.0K | -98.4% | -63.3% |
| June 30, 2023 | $643.0K | -37.8% | +35.4% |
| March 31, 2023 | $475.0K | -59.5% | -96.8% |
| September 30, 2022 | $14.95M | +1007.3% | +1347.1% |
- Avalo Therapeutics, Inc. showed a decrease of -86.6% in Total Revenue compared to the prior fiscal year.
- The most recent figure is from Avalo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: